Analgesia and unwanted benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-sensitive GABAA receptor subtype

Nature Communications

Volumn 6, Issue , 2015, Pages

  Ralvenius, William T ^a,b   Benke, Dietmar ^a,b   Acuña, Mario A ^a,b   Rudolph, Uwe ^c,d   Zeilhofer, Hanns Ulrich ^a,b,e  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Neuroscience Center Zurich   (Switzerland)

^c MCLEAN HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE; FLUMAZENIL; ARGININE; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; DIAZEPAM; HISTIDINE; HYPNOTIC SEDATIVE AGENT; MIDAZOLAM;

DRUG; GENE EXPRESSION; INHIBITION; MUTATION; PATHOLOGY; RODENT;

ANALGESIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; CHRONIC CONSTRICTION INJURY; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFECT; DRUG SENSITIVITY; FEMALE; HEAT SENSITIVITY; HUMAN; HYPERALGESIA; IMMUNOCYTOCHEMISTRY; LOCOMOTION; MALE; MOTOR COORDINATION; MOUSE; MUSCLE RELAXATION; MUSCLE STRENGTH; NONHUMAN; POINT MUTATION; PROTEIN EXPRESSION; RECEPTOR OCCUPANCY; ROTAROD TEST; SEDATION; SPECIES DIFFERENCE; SPINAL CORD DORSAL HORN; ANIMAL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; PAIN; PATHOPHYSIOLOGY; PROCEDURES; SPINAL CORD;

MUS;

ANALGESIA; ANIMALS; ARGININE; BENZODIAZEPINES; DIAZEPAM; GABA MODULATORS; GENE EXPRESSION; HISTIDINE; HYPERALGESIA; HYPNOTICS AND SEDATIVES; MALE; MICE; MIDAZOLAM; PAIN; PAIN MANAGEMENT; POINT MUTATION; RECEPTORS, GABA-A; SPINAL CORD;

EID: 84927599687     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7803     Document Type: Article

References (47)

1. Zeilhofer, H. U., Benke, D. & Yévenes, G. E. Chronic pain states: pharmacological strategies to restore diminished inhibitory spinal pain control. Annu. Rev. Pharmacol. Toxicol. 52, 111-133 (2012).
2. De Koninck, Y. Altered chloride homeostasis in neurological disorders: a new target. Curr. Opin. Pharmacol. 7, 93-99 (2007).
3. Kuner, R. Central mechanisms of pathological pain. Nat. Med. 16, 1258-1266 (2010).
4. Sandkühler, J. Models and mechanisms of hyperalgesia and allodynia. Physiol. Rev. 89, 707-758 (2009).
5. A receptor subtypes. Nature 451, 330-334 (2008).
6. A receptor function. Biochem. Soc. Trans. 34, 868-871 (2006).
7. A receptors is essential for benzodiazepine agonist binding. J. Biol. Chem. 267, 1426-1429 (1992).
8. A receptors rendered diazepam-insensitive by point-mutated α-subunits. FEBS Lett. 431, 400-404 (1998).
9. A receptors. Handb. Exp. Pharmacol. 225-247 (2005).
10. A receptor α1 subtype. Nat. Neurosci. 3, 587-592 (2000).
11. A receptor subtypes. Nature 401, 796-800 (1999).
12. Löw, K. et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290, 131-134 (2000).
13. A receptor subtypes. Nat. Rev. Drug Discov. 10, 685-697 (2011).
14. A receptors containing both α1 and α3 subunits. J. Biol. Chem. 271, 27902-27911 (1996).
15. A receptors containing two different types of α subunits in murine brain using point-mutated α subunits. J. Biol. Chem. 279, 43654-43660 (2004).
16. A receptors containing two distinct types of α subunits. J. Neurochem. 110, 244-254 (2009).
17. Bennett, G. J. & Xie, Y. K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33, 87-107 (1988).
18. A receptor subtype-selective benzodiazepine analogues in mice and rat models. J. Med. Chem. 52, 1795-1798 (2009).
19. Fischer, B. D. et al. Anxiolytic-like effects of 8-acetylene imidazobenzodiazepines in a rhesus monkey conflict procedure. Neuropharmacology 59, 612-618 (2010).
20. A receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain. Neuropharmacology 60, 626-632 (2011).
21. Drexler, B., Zinser, S., Hentschke, H. & Antkowiak, B. Diazepam decreases action potential firing of neocortical neurons via two distinct mechanisms. Anesth. Analg. 111, 1394-1399 (2010).
22. A receptors via two distinct and separable mechanisms. Nat. Neurosci. 3, 1274-1281 (2000).
23. Crestani, F. et al. Molecular targets for the myorelaxant action of diazepam. Mol. Pharmacol. 59, 442-445 (2001).
24. A receptors in mediating the anxiolytic effects of benzodiazepines. J. Neurosci. 25, 10682-10688 (2005).
25. A receptor trafficking and decreases synaptic inhibition. Proc. Natl Acad. Sci. USA 109, 18595-18600 (2012).
26. A receptor point-mutated mice. Pain 141, 233-238 (2009).
27. A receptor-positive allosteric modulators, in tests for pain, anxiety, memory and motor function. Behav. Pharmacol. 23, 790-801 (2012).
28. Nickolls, S. et al. A comparison of the α2/3/5 selective positive allosteric modulators L-838,417 and TPA023 in preclinical models of inflammatory and neuropathic pain. Adv. Pharmacol. Sci. 2011, 608912 (2011).
29. A receptorpositive allosteric modulator NS11394 [3′-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther. 327, 969-981 (2008).
30. Richards, B. L., Whittle, S. L. & Buchbinder, R. Muscle relaxants for pain management in rheumatoid arthritis. Cochrane Database Syst. Rev. 1, CD008922 (2012).
31. Corrigan, R., Derry, S., Wiffen, P. J. & Moore, R. A. Clonazepam for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst. Rev. 5, CD009486 (2012).
32. Tan, K. R. et al. Neural bases for addictive properties of benzodiazepines. Nature 463, 769-774 (2010).
33. A-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J. Comp. Neurol. 359, 154-194 (1995).
34. A-receptor subtypes in the spinal cord: an immunohistochemical study. J. Neurosci. 16, 283-297 (1996).
35. A receptors in the nucleus accumbens. Neuropsychopharmacology 39, 1805-1815 (2014).
36. A receptor subtypes in benzodiazepine-induced enhancement of brain-stimulation reward. Neuropsychopharmacology 37, 2531-2540 (2012).
37. A receptors at supraspinal level. Eur. J. Pharmacol. 370, 9-15 (1999).
38. Luger, T. J., Hayashi, T., Weiss, C. G. & Hill, H. F. The spinal potentiating effect and the supraspinal inhibitory effect of midazolam on opioid-induced analgesia in rats. Eur. J. Pharmacol. 275, 153-162 (1995).
39. Harris, J. A. & Westbrook, R. F. Effects of benzodiazepine microinjection into the amygdala or periaqueductal gray on the expression of conditioned fear and hypoalgesia in rats. Behav. Neurosci. 109, 295-304 (1995).
40. Vuilleumier, P. H., Besson, M., Desmeules, J., Arendt-Nielsen, L. & Curatolo, M. Evaluation of anti-hyperalgesic and analgesic effects of two benzodiazepines in human experimental pain: a randomized placebo-controlled study. PLoS ONE 8, e43896 (2013).
41. A receptor α2/α3 subtype-selective partial agonis. J. Psychopharmacol. 25, 329-344 (2011).
42. A receptors enhances cognition. J. Pharmacol. Exp. Ther. 316, 1335-1345 (2006).
43. A receptor subtypes: therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism. Annu. Rev. Pharmacol. Toxicol. 54, 483-507 (2014).
44. A receptors. Proc. Natl Acad. Sci. USA 99, 8980-8985 (2002).
45. A receptor subtypes in mouse spinal dorsal horn neurons and primary afferents. J. Comp. Neurol. 520, 3895-3911 (2012).
46. A receptors occurs via a genuine spinal action and does not involve supraspinal sites. Neuropsychopharmacology 39, 477-487 (2014).
47. A receptors. Neuropharmacology 51, 168-172 (2006).